Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease
University of Liverpool · Aintree University Hospital · +4 more institutions
Abstract
Lung function in chronic obstructive pulmonary disease (COPD) can be improved acutely by oral corticosteroids and bronchodilators. Whether clinical improvement can be maintained by subsequent inhaled therapy is unknown. COPD patients (n=1,022, mean prebronchodilator forced expiratory volume in one second (FEV1) 36% predicted) initially received formoterol (9 microg b.i.d.) and oral prednisolone (30 mg o.d.) for 2 weeks. After this time, patients were randomised to b.i.d. inhaled budesonide/formoterol 320/9 microg, budesonide 400 microg, formoterol 9 microg or placebo for 12 months. Postmedication FEV1 improved by 0.21 L and health-related quality of life using the St George's Respiratory Questionnaire (SGRQ)…
Citation impact
- FWCI
- 38.37
- Percentile
- 100%
- References
- 32
Authors
6- PMPeter M.A. CalverleyCorresponding
University of Liverpool, Aintree University Hospital
- WBWatchara Boonsawat
Khon Kaen University, Markusovszky Egyetemi Oktatókórház
- ZCZ. Cseke
University of Liverpool, Khon Kaen University, Aintree University Hospital
- NZNanshan Zhong
State Key Laboratory of Respiratory Disease
- SPStefan Peterson
AstraZeneca (Sweden)
Topics & keywords
- Medicine
- Budesonide
- Formoterol
- Budesonide/formoterol
- Pulmonary disease
- Intensive care medicine
- Maintenance therapy
- Asthma
- Good health and well-being